NeuroPace
NPCE | NASDAQ
$7.97
+$0.41 (+5.42%)
At close: Nov 16, 2026, 4:00 PM ET
$7.82
-$0.15 (-1.88%)
After-hours:
Nov 16, 2026, 7:39 PM ET
+5.42%
(1D)No price chart data available for 1D timeframe.
Rating
43.2
-1.0 ptsFundamentals Average
Market Sentiment Neutral
Moat Narrow
Sector Rank #440/1021 (Top 43%)
Key Statistics
Market Data
Market Cap $274.58M
1D Range
7.05 8.18
52W Range
7.05 19.29
Valuation (TTM)
PE -14.23
PB 23.89
EV/EBITDA -26.70
Valuation (NTM)
Forward PE N/A
Forward PEG 0.55
Price Target $20.50
Cash Flow
FCF Yield -4.5%
SBC Adj. FCF Yield -8.0%
SBC Impact -77.5%
Margins
Gross Margin 81.4%
Operating Margin -15.4%
FCF Margin -13.1%
Growth (CAGR)
Revenue 3Y | 5Y 16.3% |
16.1%
Dil EPS 3Y | 5Y 29.0% |
30.0%
FCF 3Y | 5Y 14.3% |
27.2%
Returns
ROA -20.0%
ROE -133.1%
ROIC -18.0%
Financial Health
Net Debt
$12.25M
Current Ratio 5.26
Interest Coverage -2.34
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at...
Sector Healthcare
Industry Medical - Devices
Employees 220
IPO Date Apr 22, 2021
Website www.neuropace.com
Fiscal Year January - December
Latest News
No news articles available yet.
Earnings
Latest Earnings
Nov 12, 2026
EPS
-$0.1
Beat +8.05%
YoY:
+9.09% REV
$23.1M
Miss -14.82%
YoY:
-15.54%Next Earnings
Mar 2, 2027
EPS Est
Pro
Rev Est
Pro
Analyst Summary
# of Analysts
3
Consensus
Buy
Price Target
$14.00
Upside
+75.66%
Buy (3)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove NPCE